Webinar Details

Big Legislative Changes: What You Need to Know to Meet the New Compliance Challenges

Previously Recorded on May 29, 2018

Two new major pieces of legislation – the Food and Drug Administration Reauthorization Act (FDARA) and the 21st Century Cures Act – will likely have serious effects on your business, and failure to comply with them may even make your operations vulnerable to shut down. This webinar will look at how these new laws, as well as CDRH's agenda in the coming years, are likely to affect medical device companies.

Participants can expect to learn:

  • The impact of new FDARA user fees
  • How FDARA provides greater transparency to industry regarding inspections
  • The proposed changes to obtaining a Certificate to Foreign Government (CFG)  
  • What to do to be prepared for the rollout of this new legislation

Steven NiedelmanSteven Niedelman serves as lead quality systems and compliance consultant to the FDA & Life Sciences practice team at King & Spalding, specializing in regulatory, enforcement and policy matters involving industries regulated by the U.S. Food and Drug Administration. He provides strategic advice, insight and guidance to the medical device, pharmaceutical, biologics and food industries to ensure compliance with the requirements of the federal Food, Drug and Cosmetic Act.

Mr. Niedelman consults with manufacturers, importers, new product developers, as well as with firms involved in or facing enforcement actions. He helps firms develop corrective action plans so their business needs are properly balanced with regulatory requirements in order to achieve compliance without compromising objectives. He provides training and guidance to industry professionals on all FDA requirements, including quality systems requirements, inspection preparedness, post-market obligations and to executives about their management responsibilities as well as FDA’s expectations.

Mr. Niedelman retired from the Food and Drug Administration in 2006 after a 34-year distinguished career, where he served as the Deputy Associate Commissioner for Regulatory Affairs and as Chief Operating Officer of the Office of Regulatory Affairs. He ensured consistent interpretation of FDA’s regulatory policies by directly overseeing offices at the headquarters of the Office of Regulatory Affairs (ORA), including the Office of Regional Operations, Office of Enforcement and Office of Criminal Investigations. Before joining the Office of Enforcement, Mr. Niedelman spent nearly 24 years throughout the Office of Compliance at the Center for Devices and Radiological Health (CDRH) in a number of management positions. During those nearly 24 years at CDRH he was responsible for implementing many of the newly created statutory requirements and drafting and shaping many of the regulations and policies affecting the sale, distribution and promotion of medical devices.

Watch the Webinar

Webinar Resources

This site uses cookies. View our cookie policy.